bioRxivNeurosciencePreprint
Profiling Lysosomal and Mitochondrial Dysfunction in Neurodegenerative Diseases Using Human Fibroblasts for Translational Therapeutic Screening
Diana M. LeiteiD, Rhianna Lenham, Philippa MalkoiD, Stuart ThomsoniD, Tim Phillips, Tatiana Rosado RosenstockiD, Naheed Rohman Mirza
Abstract
Lysosomal dysfunction and mitochondrial health are intricately connected, playing essential roles in cellular homeostasis. Lysosomes are acidic membrane-bound organelles responsible for degrading and recycling cellular waste, while mitochondria generate the energy required for cellular functions. Growing evidence implicates roles for lysosomal and mitochondrial dysfunction in neurodegenerative diseases, including Alzheimers and Parkinsons disease. With novel therapeutics targeting both the lysosomal and mitochondrial functions, robust assays for compound screening are becoming critical to evaluate modulation of both organelles in disease-relevant cellular models. Here, we investigated human fibroblasts derived from healthy donors, as well as patients with Alzheimers and Parkinsons disease, to assess their capacity to model key aspects of lysosomal and mitochondrial dysfunction. Lysosomal function was evaluated using various assays, including quantification of lysosomal proteins (TMEM175 and LAMP1), LysoTracker staining, measurement of lysosomal pH, and lysosomal enzymatic activity. Autophagic flux was assessed by measuring p62 levels as a marker of autophagy. Mitochondrial function was investigated by measuring mitochondrial calcium levels, membrane potential, oxidative stress, and mitochondrial content using MitoTracker. To explore the potential of using human fibroblasts for in vitro compound screening, we validated these assays in a 384-well high-throughput format using compounds such as chloroquine and ammonium chloride. Our findings demonstrate that human fibroblasts faithfully recapitulate lysosomal and mitochondrial dysfunctions characteristic of neurodegenerative diseases. Moreover, the use of robust assays positions these cells as a valuable platform for high-throughput screening to identify novel therapeutics targeting lysosomal and mitochondrial pathways.
- organism: human
- assay: bulk RNA-seq
- research focus: benchmarking
- research focus: drug response / drug discovery
- approach: statistical model
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Identification and small molecule rescue of mitochondrial dysfunction phenotype which converges across Leigh Syndrome and Huntington's Disease patient fibroblasts.
Naomi Hartopp, Laura V. Ellis, … Heather Mortiboys·bioRxiv·Jun 8, 2026
- Mitochondria alterations in fibroblasts from sporadic Alzheimer's disease (AD) patients correlate with AD-related clinical hallmarks
F. Eysert, P. F. Kinoshita, … M. Chami·bioRxiv·Dec 21, 2023
- Investigation of mitochondrial phenotypes in motor neurons derived by direct conversion of fibroblasts from familial ALS subjects
Evan Woo, Faiza Tasnim, … Csaba Konràd·Cell Death and DiseasePeer-reviewed·Nov 21, 2025
- A human lysosomal storage disorder toolkit for decoding proteome landscapes in cortical and dopaminergic-like induced neurons
Felix Kraus, Yuchen He, … J. Wade Harper·Proceedings of the National Academy of SciencesPeer-reviewed·Jul 1, 2026
- Decline in mitochondrial health and lysosomal acidification in human neurons during normal aging
Emilie M. Legault, Juan Pablo Izabal Gamez, Janelle Drouin‐Ouellet·bioRxiv·Sep 17, 2026
- Strategies for the modulation of mitochondrial metabolism and activity in the treatment of neurodegenerative diseases: A systematic review and meta-analysis.
Piedad Valverde-Guillén, Pedro Seoane, … Manuel Bernal-Quirós·bioRxiv·Mar 11, 2026